Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

9.36
+1.0712.91%
Pre-market: 9.31-0.0550-0.59%04:08 EDT
Volume:12.04M
Turnover:110.40M
Market Cap:544.18M
PE:-3.80
High:9.88
Open:8.29
Low:8.05
Close:8.29
52wk High:40.37
52wk Low:2.96
Shares:58.14M
Float Shares:45.54M
Volume Ratio:0.96
T/O Rate:26.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4659
EPS(LYR):-2.2601
ROE:-73.70%
ROA:-33.63%
PB:2.21
PE(LYR):-4.14

Loading ...

Capricor Tumbles as FDA Panel Meet for Duchenne Cell Therapy Adds Risk Worries

Reuters
·
Jun 26

Capricor Therapeutics to Face FDA Advisory Panel Review of Deramiocel BLA in Duchenne Muscular Dystrophy

Reuters
·
Jun 26

Capricor announces FDA advisory committee meeting to review Deramiocel BLA

TIPRANKS
·
Jun 26

Capricor Therapeutics Says Deramiocel BLA PDUFA Target Action Date Set for August 22

Reuters
·
Jun 26

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review Bla for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

THOMSON REUTERS
·
Jun 26

Capricor Therapeutics - Deramiocel Bla Pdufa Target Action Date Set for August 22, 2026

THOMSON REUTERS
·
Jun 26

Capricor presents five-year data from HOPE-2 open-label extension study

TIPRANKS
·
Jun 26

Capricor Says Deramiocel Meets Primary Endpoint in Hope-3 Phase 3 Duchenne Muscular Dystrophy Trial

Reuters
·
Jun 26

Capricor Therapeutics EVP, General Counsel Karen Krasney Sells 900 Shares for $27,000

Reuters
·
Jun 25

Analysts Offer Insights on Healthcare Companies: Odyssey Therapeutics, Inc. (ODTX), Capricor Therapeutics (CAPR) and Medtronic (MDT)

TIPRANKS
·
Jun 18

Capricor Therapeutics shareholders reject officer exculpation charter amendment at annual meeting

Reuters
·
Jun 09

Capricor Therapeutics to present at Goldman Sachs Global Healthcare Conference

Reuters
·
Jun 08

Why Capricor Therapeutics (CAPR) Is Down 10.8% After FDA Clears Key Deramiocel Inspection Step

Simply Wall St.
·
Jun 07

Capricor publishes investor presentation on deramiocel Duchenne muscular dystrophy program

Reuters
·
May 29

Capricor names Michael Maurer chief commercial officer

Reuters
·
May 29

Capricor Therapeutics files Form 3 for Chief Commercial Officer Michael T. Maurer

Reuters
·
May 29

A Look At Capricor Therapeutics (CAPR) Valuation After Deramiocel Launch Delay And Milestone Cut

Simply Wall St.
·
May 25

Capricor publishes investor presentation on deramiocel Duchenne muscular dystrophy program

Reuters
·
May 21

Capricor Faces Revenue Risk as Dependence on Nippon Shinyaku Puts Deramiocel Commercialization in Jeopardy

TIPRANKS
·
May 15

Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)

TIPRANKS
·
May 15